US3201407A - Compounds useful in the prevention of dental caries - Google Patents
Compounds useful in the prevention of dental caries Download PDFInfo
- Publication number
- US3201407A US3201407A US257743A US25774363A US3201407A US 3201407 A US3201407 A US 3201407A US 257743 A US257743 A US 257743A US 25774363 A US25774363 A US 25774363A US 3201407 A US3201407 A US 3201407A
- Authority
- US
- United States
- Prior art keywords
- compounds
- pyridoxine
- prevention
- fluorine
- monofluorophosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title description 53
- 208000002925 dental caries Diseases 0.000 title description 22
- 230000002265 prevention Effects 0.000 title description 17
- DWYMPOCYEZONEA-UHFFFAOYSA-N fluorophosphoric acid Chemical class OP(O)(F)=O DWYMPOCYEZONEA-UHFFFAOYSA-N 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 description 21
- 239000011737 fluorine Substances 0.000 description 21
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 20
- 230000002349 favourable effect Effects 0.000 description 19
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 18
- 239000002253 acid Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 125000002181 pyridoxine group Chemical group 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 239000000551 dentifrice Substances 0.000 description 9
- ZBYMCXAXDPVTHW-UHFFFAOYSA-N fluoro-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]phosphinic acid Chemical compound P(=O)(O)(F)OCC=1C(=C(C(=NC=1)C)O)CO ZBYMCXAXDPVTHW-UHFFFAOYSA-N 0.000 description 9
- 235000008160 pyridoxine Nutrition 0.000 description 9
- 239000011677 pyridoxine Substances 0.000 description 9
- 229940011671 vitamin b6 Drugs 0.000 description 9
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 8
- 150000002222 fluorine compounds Chemical class 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229940074371 monofluorophosphate Drugs 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000006072 paste Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 244000199866 Lactobacillus casei Species 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 229940112822 chewing gum Drugs 0.000 description 4
- 235000015218 chewing gum Nutrition 0.000 description 4
- 210000003298 dental enamel Anatomy 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 235000013024 sodium fluoride Nutrition 0.000 description 4
- 239000011775 sodium fluoride Substances 0.000 description 4
- -1 sodium fluorosilicate Chemical compound 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000019156 vitamin B Nutrition 0.000 description 4
- 239000011720 vitamin B Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000001013 cariogenic effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004334 fluoridation Methods 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910001512 metal fluoride Inorganic materials 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 3
- 229960002799 stannous fluoride Drugs 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000004091 cariogenic agent Substances 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940091249 fluoride supplement Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 231100000989 no adverse effect Toxicity 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- BFDWBSRJQZPEEB-UHFFFAOYSA-L sodium fluorophosphate Chemical compound [Na+].[Na+].[O-]P([O-])(F)=O BFDWBSRJQZPEEB-UHFFFAOYSA-L 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- 229940046001 vitamin b complex Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- ZXVONLUNISGICL-UHFFFAOYSA-N 4,6-dinitro-o-cresol Chemical compound CC1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O ZXVONLUNISGICL-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010043268 Tension Diseases 0.000 description 1
- 208000007642 Vitamin B Deficiency Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- DWYMPOCYEZONEA-UHFFFAOYSA-L fluoridophosphate Chemical compound [O-]P([O-])(F)=O DWYMPOCYEZONEA-UHFFFAOYSA-L 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000005649 metathesis reaction Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940005638 monofluorophosphate ion Drugs 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
- C07D213/67—2-Methyl-3-hydroxy-4,5-bis(hydroxy-methyl)pyridine, i.e. pyridoxine
Definitions
- Tooth decay is a major problem in many areas of the world. In the United States for example, it has been estimated that more than 90% of the population is afflicted with this condition.
- the vitamin B complex is well known.
- This complex includes pyridoxine (S-hydroxy 6-methyl 3,4-di(hydroxymethyl) pyridine), pyridoxyl (3-hydroxy S-hydroxymethyl 2-methyl isonicotinaldehyde), pyridoxamine (B-hydroxy S-hydroxymethyl 2-methyl 4-aminomethyl pyridine) and codecarboxylase which is the S-monophosphoric acid ester of pyridoxyl.
- salts of pyridoxine with monofluorophosphoric acid, H PFO are highly effective in the prevention of detal caries, these salts exhibiting both a direct and indirect favorable action in the prevention of dental canes.
- One object of this invention is to provide new chemical compounds useful in the prevention of dental caries.
- Another object of this invention is to provide new chemical compounds exhibiting both direct and indirect favorable actions in the prevention of dental caries.
- a further object of this invention is to provide neutral dipyridoxine nronofluorophosphate.
- An additional object of this invention is to provide acid pyridoxine monofluorophosphate.
- Yet another object of this invention is to provide compositions of matter containing one or more of the compounds thereof, said compositions being effective in the prevention of dental caries.
- n is a Whole number selected from the group consisting of one and two.
- the compounds of this invention may be conveniently prepared by the reaction of sodium monofluorophosphate with pyridoxine hydrochloride or by the interaction of monofluorophosphoric acid with pyridoxine base.
- Example 1 In the preparation of dipyridoxine monofiuorophosphate (above formula Where n is two), 14.4 g. of commercial disoclium monofluorophosphate, 41.1 g. (0.2 mole) pyridoxine hydrochloride and ml. of water were heated together until a clear solution resulted. The solution was cooled to 15 C., the crystalline precipitate filtered, washed with cold Water and dried. The yield was 35 g.
- the compound is a white, stable, non-hygroscopic crystalline product, readily soluble in water, sparingly soluble in alcohol and melting at ISO-151 C. It may be recrystallized by dissolving in hot water, adding methanol and cooling. The recrystallized material melts at 153-154 C.
- the yield of crude salt obtained (35 g.) represents 80% theory.
- commercially available disodium monofluorophosphate has a Na PFO content of 85-92% so the yield of crude salt produced in this example represents a theoretical yield actually somewhat above 80%.
- Example 2 In the preparation of acid pyridoxine monofluorophosphate (above formula where n is one), g. of pyridoxine base was dissolved in 40 ml. of warm methanol and the solution treated with an excess (20 ml.) of monotluorophosphoric acid. The resulting mixture was stirred with 200 ml. of isopropanol, cooled to C. and the precipitated compound was filtered, washed with isopropanol and dried. The yield was 10 g. (63 theory).
- This new compound is also a white, stable, non-hygroscopic crystalline product, readily soluble in Water, sparingly soluble in alcohol and exhibiting a melting point of 170175 C. It may be recrystallized by dissolving in warm water and precipitating with isopropanol. The melting point of the recrystallized compound is 175 C.
- Example 3 The respective products of Examples 1 and 2 may be interconverted, the one to the other, by appropriate reactions and manipulations which confirm the structures and the relationship between the two compounds.
- 2.69 g. (0.01 mole) of acid pyridoxine monofluorophosphate (Example 2) and 1.69 g. (0.01 mole) of pyridoxine base were dissolved in 4 ml. of hot water and the resulting solution was treated with 80 ml of isopropanol. The precipitate was filtered, washed with isopropanol and dried.
- the product had a melting point of 153-154 C. which was not depressed by mixing with a sample of the dipyridoxine monofluorophosphate prepared as described in Example 1.
- One or more of the compounds of this invention may be incorporated into solutions, lozenges, chewing gum, dentifrices and similar vehicles.
- the compounds of this invention may be incorporated into mouthwashes or may be marketed in the form of a rapidly dissolving tablet which is added to drinking water, fruit juice, milk, or the like prior to the drinking thereof.
- One particularly effective method of administration of the compounds of this invention results when they are incorporated into slowly dissolving lozenges which are held in the mouth until dissolved.
- a similarly effective method of administration is via chewing gum.
- sufficient dipyridoxine monofluorophosphate and/or acid pyridoxine monofiuorophosphate may be incorporated with a conventional chewing gum base to provide from say 0.0005 to 0.0015 g. equivalent fluorine in each stick of gum.
- acid pyridoxine monofluorophosphate has a fluorine content of 6.82%
- a stick of gum weighing one gram may contain, on the above basis, from about 7 to 22 mg. of this compound.
- the chewing of one stick of gum, formulated as above described, each day will provide not only the recommended daily dosage of fluorine necessary to achieve the well known indirect favorable effect of this element on the prevention of dental caries but also gives rise to an even more fundamental, direct favorable effect on the prevention of dental caries as will become apparent as the description of this invention proceeds. Since the acute toxicity (on the basis of equal fluorine quantities) of the monofluorophosphate ion is only one third to one half as great as the acute toxicity of the fluoride ion, the chewing during a single day of several sticks of gum formulated as above and containing as much as 1.5 mg. fluorine per stick will have no adverse effect on the user.
- the compounds of this invention may also be employed in the formulation of powder and paste type dentifrices.
- Paste type dentifrices generally contain from 10-40% water, 10-40% of a humectant, usually a polyhydric alcohol such as glycerine, and 20-60% of a scouring agent such as calcium pyrophosphate (dentifrice grade). Small amounts of other materials such as detergents, thickeners and flavoring extracts are also usually found in paste dentifrices.
- Paste dentifrices containing from about 0.15 to 6.0% by weight acid pyridoxine monofluorophosphate or from about 0.23 to 8.6% by weight dipyridoxine monofluorophosphate will have fluorine contents in the range 0.01 to 0.4%. It is preferred that the paste contain in the neighborhood of 0.1% fluorine, equivalent to a content of about 1.5% by weight acid pyridoxine monofluorophosphate or about 2.3% by weight dipyridoxine monofluorophosphate.
- the compounds of my invention have the usual indirect favorable elfect on the prevention of dental caries exhibited by fluorine containing compounds of the prior art such as stannous fluoride and sodium fluoride.
- the indirect favorable effect is the result of strengthening and hardening of the tooth enamel, thus making it less susceptible to attack by decay causing acids and bacteria involved in the production of such acids.
- the compounds of my invention have a direct favorable effect on the prevention of dental caries not manifested by prior art fluorine compounds. It is believed that this direct favorable effect of the compounds of my invention is the result of a favorable modification of the oral flora due to the action of the pyridoxine moiety of said compounds. While the explanation of the direct favorable action of the compounds of my invention is believed to be correct it is based to a certain degree upon theoretical considerations and I do not wish to be bound by any theory offered.
- the presence of the pyridoxine moiety of the compounds of my invention brings about a fundamental and favorable change in the oral flora, the population of homofermentative cariogenic bacteria, such as Lactobacillus acidophilus, being reduced while the population of heterofermentative non-cariogenic bacteria, such a L. casei, increases.
- L. casei requires the pyridoxine moiety for growth and the growth of this bacillus is, within limits, proportional to the amount of this essential nutrient present.
- L. acidoplzilus does not require the pyridoxine moiety for growth and in mixed populations containing both L. acidophilus and L. casei a goodly supply of pyridoxine tends to suppress the acidophilus population due probably to the mass action efiect of the simultaneously increased population of L. casei.
- acid pyridoxine monofluorophosphate contains almost 9 mg. of the pyridoxine moiety per milligram of fluorine content and similarly the dipyridoxine monofluorophosphate contains almost 18 mg. of the pyridoxine moiety per milligram fluorine content. Accordingly, it is seen that a lozenge or stick of chewing gum containing a suflicient amount of a compound of this invention to provide 1 mg. fluorine provides the pyridoxine moiety in an amount more than adequate to supply the daily requirements of humans for this material. Also, it is evident that by the very nature of the method of administration here employed the compounds of this invention are retained in contact with the dental plaque over considerable periods of time.
- tooth paste applied to the brush varies with the individual it is seen that one gram of a tooth paste containing 0.1% by Weight fluorine supplied by one or more of the compounds of this invention will furnish 9 to 18 mg. of the pyridoxine moiety. Routine use of a composition containing one or more compounds of this invention will furnish suflicient of the pyridoxine moiety to secure the favorable direct eifect of the compounds of this invention even in those instances where previously a deficiency of vitamin B existed due to a poor diet, nervous tension, use of certain therapeutic agents, pregnancy, et cetera.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cosmetics (AREA)
Description
United States Patent 3,291,407 CQMPOUNDS USEFUL 1N Tl-E PREVENTION OF DENTAL EARIES Alexander Galat, 126 Buckingham Road, Yonkers, N.Y. No Drawing. Filed Feb. 11, 1963, Ser. No. 257,743 4 Claims. (Cl. 260-2975) This invention relates to new chemical compound-s useful in the prevention of dental caries and to compositions of matter containing one or more of said compounds.
Tooth decay is a major problem in many areas of the world. In the United States for example, it has been estimated that more than 90% of the population is afflicted with this condition.
While the precise causes of tooth decay are still not known with certainty, it has been established that certain mouth bacteria play an important role in its development. Animal experiments have shown that tooth decay does not occur unless certain specific bacteria are present and that tooth decay is infectious and transmissa ble. These decay causing organisms can be readily destroyed or controlled by oral use of broad spectrum antibiotics, such as penicillin and the like. Unfortunately this method is not suitable because antibiotics often produce untoward side effects when used regularly and long term medication with these agents frequently results in the development of resistant strains of bacteria. In addition, such antibiotics are not sufficiently selective and destroy many useful species of oral bacteria, thus allowing other organisms, such as yeasts and fungi, to run rampant. This in turn may produce serious conditions, such as lung ailments, which may be fatal.
It has been known for some time that the presence of fluorides in very small amounts in drinking water reduces the incidence of dental caries. Also, topical application of fluoride solutions to teeth has met with considerable success. These findings have led to the large scale fluoridation of drinking water supplies in many localties where the fluoride levels are suboptimal.
One of the many difficulties encountered in the fluoridation of public water supplies resides in the fact that in many areas this water comes in contact with substances that tend to inactivate added fluorides. Thus, drinking water is frequently treated with various clays, absorbents and certain calcium, magnesium and aluminum compounds that may make the fluorine unavailable to the human organism. Fluoridation is accomplished through controlled addition of metallic fluorine compounds, such as sodium fluorosilicate, sodium fluoride, et cetera, to the water. Such compounds readily undergo ion exchange reactions that tend to bind the active fluoride ion in the form of an inactive, unavailable new compound (usually a simple or complex calcium salt thereof) While the inactive (from the decay prevention standpoint) sodium or other metal ion is released into the water.
Attempts have also been made to introduce similar metal fluorides into household items of oral hygiene, such as denti-frices, but difficulties similar to those described above have also been encountered in these efforts. Certain ingredients of dentifrices gradually inactivate the fluorine compounds incorporated into such products, with the result that the caries preventive activity of such products may decrease substantially during storage prior to use. Here too the inactivation process involves metathesis or an ion exchange reaction between the inorganic metal fluoride with another compound whereby the fluoride ion is rendered unavailable.
Even under optimum experimental conditions Where there is no inactivation of the fluoride ion as described above, the use of metal fluorides is only partially successful for the reason that the favorable action of fluo- 3,201,407 atented Aug. 17, 1965 ice rides in the prevention of dental caries is entirely indirect, the fluoride ion having no direct effect upon actual cariogenic factors such as decay causing acids and bacteria responsible-for the production thereof. Fluorides merely strengthen and harden tooth enamel and thus render it less susceptible to attack by decay causing acids and bacteria involved in the production thereof. While this strengthening and hardening effect is very valuable, it has no influence on the actual and direct causative factors involved in tooth decay and is accordingly only partially successful.
The vitamin B complex is well known. This complex includes pyridoxine (S-hydroxy 6-methyl 3,4-di(hydroxymethyl) pyridine), pyridoxyl (3-hydroxy S-hydroxymethyl 2-methyl isonicotinaldehyde), pyridoxamine (B-hydroxy S-hydroxymethyl 2-methyl 4-aminomethyl pyridine) and codecarboxylase which is the S-monophosphoric acid ester of pyridoxyl. These compounds, as the result of rapid, reversible interconversions thereof in vivo, may be considered to be biologically identical.
I have found that salts of pyridoxine with monofluorophosphoric acid, H PFO are highly effective in the prevention of detal caries, these salts exhibiting both a direct and indirect favorable action in the prevention of dental canes.
One object of this invention is to provide new chemical compounds useful in the prevention of dental caries.
Another object of this invention is to provide new chemical compounds exhibiting both direct and indirect favorable actions in the prevention of dental caries.
A further object of this invention is to provide neutral dipyridoxine nronofluorophosphate.
An additional object of this invention is to provide acid pyridoxine monofluorophosphate.
Yet another object of this invention is to provide compositions of matter containing one or more of the compounds thereof, said compositions being effective in the prevention of dental caries.
Other objects of this invention will become apparent as the description thereof proceeds.
The objects of this invention are accomplished by organic compounds of the formula:
H N/ n where n is a Whole number selected from the group consisting of one and two.
The compounds of this invention may be conveniently prepared by the reaction of sodium monofluorophosphate with pyridoxine hydrochloride or by the interaction of monofluorophosphoric acid with pyridoxine base.
For the better understanding of this invention the following illustrative but non-limiting examples thereof are given:
Example 1 In the preparation of dipyridoxine monofiuorophosphate (above formula Where n is two), 14.4 g. of commercial disoclium monofluorophosphate, 41.1 g. (0.2 mole) pyridoxine hydrochloride and ml. of water were heated together until a clear solution resulted. The solution Was cooled to 15 C., the crystalline precipitate filtered, washed with cold Water and dried. The yield was 35 g.
The compound is a white, stable, non-hygroscopic crystalline product, readily soluble in water, sparingly soluble in alcohol and melting at ISO-151 C. It may be recrystallized by dissolving in hot water, adding methanol and cooling. The recrystallized material melts at 153-154 C.
Assuming that the disodium monofluorophosphate employed in this example was 100% pure, the yield of crude salt obtained (35 g.) represents 80% theory. However, commercially available disodium monofluorophosphate has a Na PFO content of 85-92% so the yield of crude salt produced in this example represents a theoretical yield actually somewhat above 80%.
Example 2 In the preparation of acid pyridoxine monofluorophosphate (above formula where n is one), g. of pyridoxine base was dissolved in 40 ml. of warm methanol and the solution treated with an excess (20 ml.) of monotluorophosphoric acid. The resulting mixture was stirred with 200 ml. of isopropanol, cooled to C. and the precipitated compound was filtered, washed with isopropanol and dried. The yield was 10 g. (63 theory).
This new compound is also a white, stable, non-hygroscopic crystalline product, readily soluble in Water, sparingly soluble in alcohol and exhibiting a melting point of 170175 C. It may be recrystallized by dissolving in warm water and precipitating with isopropanol. The melting point of the recrystallized compound is 175 C.
Example 3 The respective products of Examples 1 and 2 may be interconverted, the one to the other, by appropriate reactions and manipulations which confirm the structures and the relationship between the two compounds. As an example of such a conversion, 2.69 g. (0.01 mole) of acid pyridoxine monofluorophosphate (Example 2) and 1.69 g. (0.01 mole) of pyridoxine base were dissolved in 4 ml. of hot water and the resulting solution was treated with 80 ml of isopropanol. The precipitate was filtered, washed with isopropanol and dried. The product had a melting point of 153-154 C. which was not depressed by mixing with a sample of the dipyridoxine monofluorophosphate prepared as described in Example 1.
Methods and means for the conversion of the product of Example 1 to that of Example 2 will now be readily apparent to those skilled in the chemical art.
One or more of the compounds of this invention may be incorporated into solutions, lozenges, chewing gum, dentifrices and similar vehicles. Thus, the compounds of this invention may be incorporated into mouthwashes or may be marketed in the form of a rapidly dissolving tablet which is added to drinking water, fruit juice, milk, or the like prior to the drinking thereof.
One particularly effective method of administration of the compounds of this invention results when they are incorporated into slowly dissolving lozenges which are held in the mouth until dissolved. A similarly effective method of administration is via chewing gum. Thus, sufficient dipyridoxine monofluorophosphate and/or acid pyridoxine monofiuorophosphate may be incorporated with a conventional chewing gum base to provide from say 0.0005 to 0.0015 g. equivalent fluorine in each stick of gum. Since acid pyridoxine monofluorophosphate has a fluorine content of 6.82%, a stick of gum weighing one gram may contain, on the above basis, from about 7 to 22 mg. of this compound. Similarly, since the fluorine content of dipyridoxine monofluorophosphate is 4.34%, from 11.5 to 35 mg. of this salt of lower fluorine content incorporated in a gum stick weighing one gram will provide 0.5 to 1.5 mg. equivalent fluorine per stick.
The chewing of one stick of gum, formulated as above described, each day will provide not only the recommended daily dosage of fluorine necessary to achieve the well known indirect favorable effect of this element on the prevention of dental caries but also gives rise to an even more fundamental, direct favorable effect on the prevention of dental caries as will become apparent as the description of this invention proceeds. Since the acute toxicity (on the basis of equal fluorine quantities) of the monofluorophosphate ion is only one third to one half as great as the acute toxicity of the fluoride ion, the chewing during a single day of several sticks of gum formulated as above and containing as much as 1.5 mg. fluorine per stick will have no adverse effect on the user.
The compounds of this invention may also be employed in the formulation of powder and paste type dentifrices. Paste type dentifrices generally contain from 10-40% water, 10-40% of a humectant, usually a polyhydric alcohol such as glycerine, and 20-60% of a scouring agent such as calcium pyrophosphate (dentifrice grade). Small amounts of other materials such as detergents, thickeners and flavoring extracts are also usually found in paste dentifrices. By incorporating a suflicient amount of one or more of the compounds of this invention in a paste dentifrice to produce a formula having a fluorine content within the approximate range 0.01-0.4% by weight results in a material exhibiting both direct and indirect favorable effects on the prevention of dental caries. Paste dentifrices containing from about 0.15 to 6.0% by weight acid pyridoxine monofluorophosphate or from about 0.23 to 8.6% by weight dipyridoxine monofluorophosphate will have fluorine contents in the range 0.01 to 0.4%. It is preferred that the paste contain in the neighborhood of 0.1% fluorine, equivalent to a content of about 1.5% by weight acid pyridoxine monofluorophosphate or about 2.3% by weight dipyridoxine monofluorophosphate.
The compounds of my invention have the usual indirect favorable elfect on the prevention of dental caries exhibited by fluorine containing compounds of the prior art such as stannous fluoride and sodium fluoride. As previously stated, the indirect favorable effect is the result of strengthening and hardening of the tooth enamel, thus making it less susceptible to attack by decay causing acids and bacteria involved in the production of such acids.
In addition to this indirect favorable etfect and of even greater importance, the compounds of my invention have a direct favorable effect on the prevention of dental caries not manifested by prior art fluorine compounds. It is believed that this direct favorable effect of the compounds of my invention is the result of a favorable modification of the oral flora due to the action of the pyridoxine moiety of said compounds. While the explanation of the direct favorable action of the compounds of my invention is believed to be correct it is based to a certain degree upon theoretical considerations and I do not wish to be bound by any theory offered.
The presence of the pyridoxine moiety of the compounds of my invention brings about a fundamental and favorable change in the oral flora, the population of homofermentative cariogenic bacteria, such as Lactobacillus acidophilus, being reduced while the population of heterofermentative non-cariogenic bacteria, such a L. casei, increases. L. casei requires the pyridoxine moiety for growth and the growth of this bacillus is, within limits, proportional to the amount of this essential nutrient present. L. acidoplzilus does not require the pyridoxine moiety for growth and in mixed populations containing both L. acidophilus and L. casei a goodly supply of pyridoxine tends to suppress the acidophilus population due probably to the mass action efiect of the simultaneously increased population of L. casei.
It will be noted that acid pyridoxine monofluorophosphate contains almost 9 mg. of the pyridoxine moiety per milligram of fluorine content and similarly the dipyridoxine monofluorophosphate contains almost 18 mg. of the pyridoxine moiety per milligram fluorine content. Accordingly, it is seen that a lozenge or stick of chewing gum containing a suflicient amount of a compound of this invention to provide 1 mg. fluorine provides the pyridoxine moiety in an amount more than adequate to supply the daily requirements of humans for this material. Also, it is evident that by the very nature of the method of administration here employed the compounds of this invention are retained in contact with the dental plaque over considerable periods of time. Although the quantity of tooth paste applied to the brush varies with the individual it is seen that one gram of a tooth paste containing 0.1% by Weight fluorine supplied by one or more of the compounds of this invention will furnish 9 to 18 mg. of the pyridoxine moiety. Routine use of a composition containing one or more compounds of this invention will furnish suflicient of the pyridoxine moiety to secure the favorable direct eifect of the compounds of this invention even in those instances where previously a deficiency of vitamin B existed due to a poor diet, nervous tension, use of certain therapeutic agents, pregnancy, et cetera.
It is seen that the overall effect of the compounds of this invention is to strengthen the tooth against cariogenic agents and simultaneously to weaken the intensity of the attack by such agents. The value and effectiveness of this dual type of anti-caries activity is evident. The strengthening of the tooth enamel with concurrent reduction of cariogenic agents is obviously a highly desirable and highly efiective method of combatting tooth decay.
As would be expected in view of the above discussion, the full benefits that follow the employment of the compounds of my invention are not revealed by conventional in vitro testing procedures. Thus, measuring the rate of attack, in vitro, of an acid on a sample of tooth enamel that has been treated with a compound of this invention measures only the indirect favorable action of said compound and accordingly would indicate that the compounds of this invention are similar in activity to the exclusively indirect acting compounds of the prior art such as stannous fluoride and sodium fluoride. However, the great superiority of the compounds of this invention over prior art compounds is revealed by biological testing under conditions of actual use, employing either human or animal (e.g., hamster) subjects. Such tests not only reveal the superiority of the compounds of this invention over the exclusively indirect acting compounds of the prior art but also clearly indicate that the favorable action of the compounds of this invention is greater than is to be expected on the basis of the sum of the individual actions of the pyridoxine moiety and the fluorine containing moiety. It is believed that this observed synergism is due in some measure to the unusual composition of the finorine containing moiety, i.e., the PFO ion, particularly to the phosphorus content thereof and even more to the presence of the modified phosphate ion.
An obvious corollary advantage of the combined direct and indirect acting compounds of this invention is that a significant and useful portion of their activity is retained even under highly adverse circumstances. Thus, as pointed out previously, in the presence of certain substances in drinking water or in the diet or in products of oral hygiene, the fluoride ion may become bound and physiologically unavailable. Only the anion is biologically active in inorganic fluorine compounds of the prior art such as sodium fluoride, stannous fluoride, and the like. Accordingly, the binding of the anion renders these compounds biologically inactive. In contrast, both the cationic and the anionic moieties of the compounds of this invention are biologically active. Accordingly, these compounds preserve a substantial part of their activity even when the availability of the fluorine containing moiety is reduced or destroyed since condition-s which affect the availability of fluorine to the organism have no eflect upon the biological availability of pyridoxine.
Since the pyridoxine moiety of the compounds of this invention actually acts topically in the oral cavity it is doubtful if even the most severe vitamin B deficiency would have any adverse effect on the direct favorable effect of the compounds of this invention in the prevention of tooth decay. However, in the unlikely event that conditions affecting adversely the availability of vitamin B to the organism (such as stress, hormone medication, pregnancy, and the like) had a simultaneous adverse effect on the direct activity of the compounds of this invention in the prevention of dental caries, even so the indirect favorable .action of these compounds would remain since such conditions have no adverse effect on the biological availability of the fluorine bearing moiety of the compounds of this invention.
Be it remembered that While this invention has been described in connection with specific details and specific embodiments thereof, these details and embodiments are illustrative only and are not to be considered limitations on the spirit and scope of said invention except in so far as these may be incorporated in the appended claims.
I claim:
1. Monofluorophosphoric acid salts of members of the vitamin B complex.
2. Monofiuorophosphoric acid salts of pyridoxine.
3. Dipyridoxine monofiuorophosphate.
4. Acid pyridoxine monofluorophosphate.
References Cited by the Examiner UNITED STATES PATENTS 2,422,622 6/47 Harris 260--297.5 2,732,379 l/ 5 6 Webb 260297.5 3,105,013 9/63 Saul 16793 3,105,798 10/63 Holliday 167-93 3,119,743 1/ 64 Ericsson 16793 FOREIGN PATENTS 547,208 5/56 Belgium.
OTHER REFERENCES Newton: Chem. Abst., vol. 50, 1956, page 10289d. Shourie et al.:. J. Dent. Res, vol. 29, pp. 523-533 (1950).
WALTER A. MODANCE, Primary Examiner.
FRANK CACCIAPAGLIA, In, Examiner.
Claims (1)
1. MONOFLUOROPHOSPHORIC ACID SALTS OF MEMBERS OF THE VITAMIN B6 COMPLEX.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US257743A US3201407A (en) | 1963-02-11 | 1963-02-11 | Compounds useful in the prevention of dental caries |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US257743A US3201407A (en) | 1963-02-11 | 1963-02-11 | Compounds useful in the prevention of dental caries |
Publications (1)
Publication Number | Publication Date |
---|---|
US3201407A true US3201407A (en) | 1965-08-17 |
Family
ID=22977563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US257743A Expired - Lifetime US3201407A (en) | 1963-02-11 | 1963-02-11 | Compounds useful in the prevention of dental caries |
Country Status (1)
Country | Link |
---|---|
US (1) | US3201407A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2523363A1 (en) * | 1974-05-31 | 1975-12-11 | Gaba Ag | ORAL AND DENTAL CARE PRODUCTS |
WO2006066822A1 (en) * | 2004-12-17 | 2006-06-29 | S & C Polymer, Silicon- Und Composite Spezialitäten Gmbh | Teeth whitening agents |
US20070053848A1 (en) * | 2003-08-26 | 2007-03-08 | Stockel Richard F | Antimicrobial materials for dental care applications |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE547208A (en) * | 1955-04-25 | |||
US2422622A (en) * | 1942-01-24 | 1947-06-17 | Merck & Co Inc | Synthesis of vitamin b6 |
US2732379A (en) * | 1956-01-24 | |||
US3105013A (en) * | 1961-09-14 | 1963-09-24 | Bristol Myers Co | Fluoride dentifrices containing calcined aluminum silicate abrasives |
US3105798A (en) * | 1958-05-29 | 1963-10-01 | Procter & Gamble | Dentifrice composition |
US3119743A (en) * | 1959-08-07 | 1964-01-28 | Ericsson Sten Yngve | Alkali metal monofluorophosphate and calcium carbonate dentifrice |
-
1963
- 1963-02-11 US US257743A patent/US3201407A/en not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2732379A (en) * | 1956-01-24 | |||
US2422622A (en) * | 1942-01-24 | 1947-06-17 | Merck & Co Inc | Synthesis of vitamin b6 |
BE547208A (en) * | 1955-04-25 | |||
US3105798A (en) * | 1958-05-29 | 1963-10-01 | Procter & Gamble | Dentifrice composition |
US3119743A (en) * | 1959-08-07 | 1964-01-28 | Ericsson Sten Yngve | Alkali metal monofluorophosphate and calcium carbonate dentifrice |
US3105013A (en) * | 1961-09-14 | 1963-09-24 | Bristol Myers Co | Fluoride dentifrices containing calcined aluminum silicate abrasives |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2523363A1 (en) * | 1974-05-31 | 1975-12-11 | Gaba Ag | ORAL AND DENTAL CARE PRODUCTS |
US20070053848A1 (en) * | 2003-08-26 | 2007-03-08 | Stockel Richard F | Antimicrobial materials for dental care applications |
WO2006066822A1 (en) * | 2004-12-17 | 2006-06-29 | S & C Polymer, Silicon- Und Composite Spezialitäten Gmbh | Teeth whitening agents |
US20080260660A1 (en) * | 2004-12-17 | 2008-10-23 | Jurgen Engelbrecht | Teeth Whitening Agents |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69209190T2 (en) | Use of triclosan in the manufacture of a medicament for inhibiting cyclooxygenase | |
US4522806A (en) | Oral compositions for hexetidine and zinc salts for the synergistic inhibition of dental plaque | |
CN1909875B (en) | Oral care compositions comprising increased bioavailable levels of quaternary ammonium antimicrobials | |
DE69618786T2 (en) | HEAT GENERATING TOOTHPASTE | |
US6610276B2 (en) | Multi-functional dental composition | |
DE69924265T2 (en) | MOUTH CARE PRODUCTS | |
US4272513A (en) | Stabilized oral composition | |
US5298237A (en) | Gel composition for reduction of gingival inflammation and retardation of dental plaque | |
EP0510158B1 (en) | Improved anti-plaque compositions comprising a combination of morpholinoamino alcohol and metal salts | |
AU7444087A (en) | Use of usnic acid to prevent dental caries | |
US4661342A (en) | Oral compositions comprising hydroxamic acids and salts thereof | |
US4618489A (en) | Dental compositions and method of use therefor | |
US4430324A (en) | Ammonium fluorometallate containing compositions | |
DE69004403T2 (en) | Oral preparations. | |
US3201407A (en) | Compounds useful in the prevention of dental caries | |
US20080274206A1 (en) | Stabilised Oxygen Releasing Composition | |
US9301911B2 (en) | Composition comprising tauroursodeoxycholic acid | |
GB2151478A (en) | Antiplaque/antigingivitis compositions | |
DE69306404T2 (en) | ORAL CARE ANTIBACTERIAL ACTIVITY | |
JP3336688B2 (en) | Oral composition | |
US4296095A (en) | Dental and mouth care preparations | |
JP2002193777A (en) | Oral composition | |
JPH07133222A (en) | Glucosyl transferase inhibitor | |
Seppä et al. | Caries prevention by two fluoride varnishes in Osborne-Mendel rats | |
JPH089529B2 (en) | Oral composition |